多西他赛联合洛铂腹腔灌注治疗晚期卵巢癌患者的临床疗效
|
摘要
目的分析多西他赛联合洛铂腹腔灌注治疗晚期卵巢癌患者的临床疗效。方法按照随机平行方法分组,将本院2014年5月至2018年5月的78例晚期卵巢癌患者,分为甲组和乙组。甲组通过多西他赛联合洛铂腹腔灌注化疗,乙组通过多西他赛联合卡铂静脉化疗,对比两组的临床效果。结果甲组和乙组治疗总有效率的数据对比为:84.61%、61.54%,差异有统计学意义(P<0.05)。甲组和乙组的不良反应发生率分别为:33.33%、30.77%,差异无统计学意义。结论多西他赛联合洛铂腹腔灌注治疗晚期卵巢癌,尤其是伴腹水的患者,可达到较好的临床效果,且不会产生严重的不良反应,值得在晚期卵巢癌治疗中应用、推广。
Objective To analyze the clinical efficacy of intraperitoneal infusion of docetaxel plus lobaplatin in the treatment of advanced ovarian cancer. Methods According to the randomized parallel method, 78 patients with advanced ovarian cancer were divided into group A and group B.Group A received intraperitoneal chemotherapy with docetaxel plus lobaplatin, and group B received intravenous chemotherapy with docetaxel plus carboplatin. The clinical effects of the two groups were compared. Results The total effective rate of group A and group B was 84.61% and 61.54%.There was statistical significance in two groups(P<0.05). The incidence of adverse reactions in group A and B were 33.33% and 30.77%, respectively. There was no significant difference between the two groups. Conclusion Docetaxel plus lobaplatin intraperitoneal infusion can achieve good clinical effect in the treatment of advanced ovarian cancer, especially in patients with ascites, without serious adverse reactions. It is worthy of application and promotion in the treatment of advanced ovarian cancer.
Objective To analyze the clinical efficacy of intraperitoneal infusion of docetaxel plus lobaplatin in the treatment of advanced ovarian cancer. Methods According to the randomized parallel method, 78 patients with advanced ovarian cancer were divided into group A and group B.Group A received intraperitoneal chemotherapy with docetaxel plus lobaplatin, and group B received intravenous chemotherapy with docetaxel plus carboplatin. The clinical effects of the two groups were compared. Results The total effective rate of group A and group B was 84.61% and 61.54%.There was statistical significance in two groups(P<0.05). The incidence of adverse reactions in group A and B were 33.33% and 30.77%, respectively. There was no significant difference between the two groups. Conclusion Docetaxel plus lobaplatin intraperitoneal infusion can achieve good clinical effect in the treatment of advanced ovarian cancer, especially in patients with ascites, without serious adverse reactions. It is worthy of application and promotion in the treatment of advanced ovarian cancer.
引文
[1]李楠,杨亮,孙亚楠,等.腹腔热灌注联合多西他赛、奥沙利铂静脉化疗治疗晚期卵巢癌疗效观察[J].现代妇产科进展,2017,26(7):493-496.
[2]李娜,高家志,朱颖,等.新辅助化疗联合洛铂术中腹腔灌注在卵巢癌中的效果评价及其机制研究[J].中国医院药学杂志,2016,36(7):582-584.
[3]武海涛,杨肖军,孙建华,等.洛铂联合多西他赛行肿瘤细胞减灭术加腹腔热灌注化疗治疗腹膜癌的临床观察[J].肿瘤防治研究,2016,43(2):150-157.
[4]武海涛,姬忠贺,张倩,等.洛铂联合多西他赛行肿瘤细胞减灭术加腹腔热灌注化疗治疗同时性胃癌腹膜癌[J].中国肿瘤临床,2016,43(4):146-151.
[5]邢雪花,王琳,盛莉,等.顺铂或洛铂腹腔化疗联合微波热疗治疗癌性腹水的临床观察[J].中华肿瘤防治杂志,2014,21(17):1376-1378.
[6]王美清,程小珍,毛山山,等.洛铂联合多西他赛对宫颈癌的临床疗效观察[J].中国现代医学杂志,2014,24(23):84-87.
[7]辛国华,侯继申,张志民.洛铂、多西他赛和艾迪注射液联合用药对72例ⅢB期非小细胞肺癌的综合疗效分析[J].中药材,2014,37(4):722-725.
[8]Wu Jianwen,Du Zhiqiang,Li Dan,et al.The efficacy of Rb combined with docetaxel in the treatment of recurrent and metastatic ovarian cancer[J].Guangdong medicine,2013,34(6):944-946.
[9]Liang Xiuju,Chu Huili,Wang Jun,et al.Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia for advanced ovarian cancer[J].Chinese Cancer Clinical,2013,40(17):1051-1054.
[10]Bingye Hong,Zheng Haiping,blue east,et al.A comparative study of SOX combined with docetaxel intraperitoneal perfusion and DOS regimen in the treatment of advanced gastric cancer with carcinomatous ascites[J].Chinese tumor prevention and control journal,2016,23(16):1085-1089.
[11]张晶,胡泽成,陈忠东.静脉联合洛铂腹腔恒温循环热灌注化疗对晚期卵巢癌的疗效研究[J].中国医学创新,2015,12(11):1-4.
[12]鲁亮,李杭,杨飞月,等.顺铂与洛铂腹腔灌注治疗晚期卵巢癌术后合并腹腔积液比较观察[J].肿瘤基础与临床,2014,27(4):314-316.
[13]李新春,李瑛花.洛铂联合多西他赛治疗复发性卵巢癌的疗效[J].中南大学学报,2014,39(11):1131-1136.
[14]王美清,程小珍,毛山山,等.洛铂联合多西他赛对宫颈癌的临床疗效观察[J].中国现代医学杂志,2014,24(23):84-87.
[15]熊勇,李小兵,徐满珍,等.洛铂和培美曲塞联合治疗复发性晚期卵巢癌的效果及安全性[J].当代医学,2016,22(35):173-174.
[16]黄云辉,桂黎.奥沙利铂联合多西他赛治疗卵巢癌的临床效果观察[J].当代医学,2014,20(9):142-143.
[2]李娜,高家志,朱颖,等.新辅助化疗联合洛铂术中腹腔灌注在卵巢癌中的效果评价及其机制研究[J].中国医院药学杂志,2016,36(7):582-584.
[3]武海涛,杨肖军,孙建华,等.洛铂联合多西他赛行肿瘤细胞减灭术加腹腔热灌注化疗治疗腹膜癌的临床观察[J].肿瘤防治研究,2016,43(2):150-157.
[4]武海涛,姬忠贺,张倩,等.洛铂联合多西他赛行肿瘤细胞减灭术加腹腔热灌注化疗治疗同时性胃癌腹膜癌[J].中国肿瘤临床,2016,43(4):146-151.
[5]邢雪花,王琳,盛莉,等.顺铂或洛铂腹腔化疗联合微波热疗治疗癌性腹水的临床观察[J].中华肿瘤防治杂志,2014,21(17):1376-1378.
[6]王美清,程小珍,毛山山,等.洛铂联合多西他赛对宫颈癌的临床疗效观察[J].中国现代医学杂志,2014,24(23):84-87.
[7]辛国华,侯继申,张志民.洛铂、多西他赛和艾迪注射液联合用药对72例ⅢB期非小细胞肺癌的综合疗效分析[J].中药材,2014,37(4):722-725.
[8]Wu Jianwen,Du Zhiqiang,Li Dan,et al.The efficacy of Rb combined with docetaxel in the treatment of recurrent and metastatic ovarian cancer[J].Guangdong medicine,2013,34(6):944-946.
[9]Liang Xiuju,Chu Huili,Wang Jun,et al.Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia for advanced ovarian cancer[J].Chinese Cancer Clinical,2013,40(17):1051-1054.
[10]Bingye Hong,Zheng Haiping,blue east,et al.A comparative study of SOX combined with docetaxel intraperitoneal perfusion and DOS regimen in the treatment of advanced gastric cancer with carcinomatous ascites[J].Chinese tumor prevention and control journal,2016,23(16):1085-1089.
[11]张晶,胡泽成,陈忠东.静脉联合洛铂腹腔恒温循环热灌注化疗对晚期卵巢癌的疗效研究[J].中国医学创新,2015,12(11):1-4.
[12]鲁亮,李杭,杨飞月,等.顺铂与洛铂腹腔灌注治疗晚期卵巢癌术后合并腹腔积液比较观察[J].肿瘤基础与临床,2014,27(4):314-316.
[13]李新春,李瑛花.洛铂联合多西他赛治疗复发性卵巢癌的疗效[J].中南大学学报,2014,39(11):1131-1136.
[14]王美清,程小珍,毛山山,等.洛铂联合多西他赛对宫颈癌的临床疗效观察[J].中国现代医学杂志,2014,24(23):84-87.
[15]熊勇,李小兵,徐满珍,等.洛铂和培美曲塞联合治疗复发性晚期卵巢癌的效果及安全性[J].当代医学,2016,22(35):173-174.
[16]黄云辉,桂黎.奥沙利铂联合多西他赛治疗卵巢癌的临床效果观察[J].当代医学,2014,20(9):142-143.